Currently, there is no class action lawsuit against Novo Nordisk regarding Rybelsus, nor are there any ongoing class action lawsuits regarding other semaglutide diabetes medications
Last year, FDAacting through the Office of Prescription Drug Promotion (OPDP) within the Center for Drug Evaluation and Research (CDER)issued a high volume of untitled and warning letters as part of a broader push against directtoconsumer (DTC) drug advertising, including 58 letters addressing claims about compounded GLP1s (e.g., semaglutide and tirzepatide) and other compounded products (e.g., sildenafil and tadalafil).[2] By mid2026, activity appeared to taper offraising the question whether FDA had shifted priorities, for example due to personnel changes, or simply paused the effort
Research suggests that this interaction might provide insight into pulsatile hormone dynamics, metabolic signaling integration, and cellular regenerative pathways
Phentermine-topiramate (Qsymia) is the strongest fully oral, currently available weight loss medication at 8-10% average weight loss
According to the summary of product characteristics, all patients were first prescribed with semaglutide 0.25 mg
Hahn, V
